N@N

Bull & Lifshitz, LLP Announces Investigation of Pharmaceutical Product Development, Inc.

_{//health-fitness.news-articles.net/content/2011/ .. n-of-pharmaceutical-product-development-inc.html}
^{Published in Health and Fitness on Thursday, October 27th 2011 at 7:05 GMT by Market Wire}  

NEW YORK--([ BUSINESS WIRE ])--Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Pharmaceutical Product Development, Inc. (NASDAQ: [ PPDI ]) (referred to as "PPD" or the aCompanya) to affiliates of The Carlyle Group ("Carlyle") and Hellman & Friedman LP (aHellman & Friedmana) in a cash transaction valued at approximately $3.9 billion.

Under the terms of the agreement, Carlyle and Hellman & Friedman will acquire all of the outstanding common shares of PPD for $33.25 per share in cash. The transaction is currently expected to close in the fourth quarter of 2011.

Bull & Lifshitz, LLP's investigation is focused on whether the proposed deal provides adequate value to the Companyas shareholders.

If you are a holder of PPD common stock and want to discuss your legal rights, you may e-mail or call Bull & Lifshitz, LLP who will, without obligation or cost to you, attempt to answer your questions.

If you are a shareholder of PPD and would like more information about our investigation, please contactJoshua M. Lifshitz, Esq. by telephone at (866) 313-6222 or by sending an e-mail including your contact information to: [ counsel@nyclasslaw.com ]. All e-mail correspondence should make reference to PPD.

Bull & Lifshitz, LLP is a New York City-based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please visit our website at [ www.nyclasslaw.com ].

ATTORNEY ADVERTISING. 2011 Bull & Lifshitz, LLP. The law firm responsible for this advertisement is Bull & Lifshitz, LLP, 18 East 41^st Street, New York, New York 10017, (212) 213-6222. Prior results do not guarantee or predict a similar outcome with respect to any future matter.